Jun 23, 2022 | Featured, ICER
On June 14, 2022, ICER released its draft evidence report, “AMX0035 and Oral Edaravone for Amyotrophic Lateral Sclerosis.” This document provides a framework for considering which aspects of two potential treatments for Amyotrophic Lateral Sclerosis (ALS) are...
Read more
May 2, 2022 | Featured, ICER
On April 13, 2022, ICER released its draft evidence report, “Betibeglogene Autotemcel for Beta Thalassemia.” This document provides a framework for considering what aspects of betibeglogene autotemcel (beti-cel) – a potential curative new gene therapy for beta...
Read more
Apr 7, 2022 | Featured, ICER, Statements
Flawed drug pricing approach fails to meet rare disease patient needs WASHINGTON — Patients Rising Executive Director Terry Wilcox today released the following statement regarding the Institute for Clinical and Economic Review’s (ICER) white paper, “The Next...
Read more
